Whitehawk Therapeutics在2025年AACR-NCI-EOTTC分子靶点和癌症治疗国际会议上展示了来自超过157，000个肿瘤样本的蛋白质酪氨酶7分析的数据

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today presented data from a real-world analysis of Protein Tyrosine Kinase 7 (PTK7) at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. As part of a collaboration between Whitehawk and Tempus AI, the analysis evaluated real-world data from the Tempus AI database and the Clinical Proteomic Tumor Analysis Consortium to, for the first time, robustly characterize PTK7 expression.

PTK7 is an oncofetal transmembrane pseudokinase that drives early embryonic development, has restricted expression in adult tissues and frequent overexpression in a wide range of cancers. There are no approved PTK7-directed ADCs.